EZH2 mutations have emerged as important therapeutic targets in cancer, with the EZH2 inhibitor tazemetostat gaining FDA approval in 2020 for the treatment of patients with advanced epithelioid sarcoma and follicular lymphoma2–4. This evidence concerns the gene EZH2 and epithelioid sarcoma.